These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35389481)

  • 1. Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study.
    Azuma T; Misaki K; Kusaoi M; Suzuki Y; Higa S; Kumon Y; Yoshitama T; Naniwa T; Yamada S; Okano T; Takeuchi K; Ikeda K; Higami K; Inoo M; Sawada T; Kang C; Hayashi M; Nagaya Y; Hagiwara T; Shono E; Himeno S; Tanaka E; Inoue E; Yoshizawa Y; Kadode M; Yamanaka H; Harigai M
    Mod Rheumatol; 2023 Mar; 33(2):271-278. PubMed ID: 35389481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study.
    Tanaka Y; Matsubara T; Hashizume K; Amano N; Takeuchi T
    Mod Rheumatol; 2022 Apr; 32(3):500-507. PubMed ID: 34897499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
    Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.
    Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G
    Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of subcutaneous abatacept in biologic-naïve RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study).
    Tamura N; Azuma T; Misaki K; Yamaguchi R; Hirano F; Sugiyama E; Kanai D; Murakawa Y; Oribe M; Kimata T; Aoki K; Sugiura T; Takasugi K; Takakubo Y; Tomita Y; Isozaki T; Nanki T; Katsuyama N; Kuroiwa T; Oshikawa H; Kaneko M; Fujinaga H; Saito K; Tanaka E; Inoue E; Yoshizawa Y; Matsumoto S; Yamanaka H; Harigai M
    Mod Rheumatol; 2022 Aug; 32(5):846-856. PubMed ID: 34915575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
    Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P
    Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis.
    Takahashi N; Kojima T; Kida D; Kaneko A; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Hanabayashi M; Kato T; Funahashi K; Hayashi M; Tsuboi S; Kanayama Y; Sobue Y; Asai N; Matsumoto T; Watanabe T; Asai S; Ishiguro N
    Clin Rheumatol; 2019 Sep; 38(9):2451-2459. PubMed ID: 31102087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis.
    Wu C; Hu Y; Schafer P; Connolly SE; Wong R; Nielsen SH; Bay-Jensen AC; Emery P; Tanaka Y; Bykerk VP; Bingham CO; Huizinga TW; Fleischmann R; Liu J
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36585217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Takemoto T; Terabe K; Asai N; Ishiguro N
    J Rheumatol; 2015 May; 42(5):786-93. PubMed ID: 25834204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI).
    Misaki K; Tamura N; Azuma T; Shinoda K; Tanaka M; Fujiwara H; Tsuboi H; Kasama T; Yoshimi R; Hanyu T; Kusaka Y; Hirao M; Onishi M; Uchino A; Izumiyama T; Yang KS; Ogawa N; Matsui K; Kurasawa K; Kawaai S; Yasuoka H; Okumura N; Ueda Y; Tanaka E; Inoue E; Tsuritani K; Matsumoto S; Yamanaka H; Harigai M
    Mod Rheumatol; 2024 Feb; 34(2):297-306. PubMed ID: 37233722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
    Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
    Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
    Keystone EC; Ahmad HA; Yazici Y; Bergman MJ
    Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
    Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
    Takahashi N; Fujibayashi T; Kida D; Hirano Y; Kato T; Kato D; Saito K; Kaneko A; Yabe Y; Takagi H; Oguchi T; Miyake H; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Takemoto T; Terabe K; Asai N; Yoshioka Y; Ishiguro N; Kojima T
    Rheumatol Int; 2015 Oct; 35(10):1707-16. PubMed ID: 25991396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.
    Emery P; Burmester GR; Bykerk VP; Combe BG; Furst DE; Barré E; Karyekar CS; Wong DA; Huizinga TW
    Ann Rheum Dis; 2015 Jan; 74(1):19-26. PubMed ID: 25367713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study.
    Emery P; Tanaka Y; Bykerk VP; Bingham CO; Huizinga TWJ; Citera G; Huang KG; Wu C; Connolly SE; Elbez Y; Wong R; Lozenski K; Fleischmann R
    Arthritis Res Ther; 2023 Apr; 25(1):67. PubMed ID: 37087459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.
    Takeuchi T; Matsubara T; Urata Y; Suematsu E; Ohta S; Honjo S; Abe T; Yamamoto A; Miyasaka N;
    Mod Rheumatol; 2014 Sep; 24(5):744-53. PubMed ID: 24754273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.